News

20Dec, 2018

CIRCULOGENE to Launch Comprehensive, 20-Fusion NTRK Biomarker Testing in Early 2019

FOR IMMEDIATE RELEASE DATE: December 20, 2018 CIRCULOGENE to Launch Comprehensive, 20-Fusion NTRK Biomarker Testing in Early 2019 Proprietary, cfRNA-enriched, real-time PCR testing rapidly identifies all patients with NTRK fusion-positive cancers potentially eligible for new TRK [...]

19Sep, 2018

CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing

CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers   BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has [...]

19Jun, 2018

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer BIRMINGHAM, Ala.– [...]